premargin

Element List	Explanation
Introduction	The Saudi Pharmaceutical and Medical Supplies Company (SPIMACO) announces the signing of a contract with Boston Oncology Arabia Limited to transfer technology and enable local manufacturing of four specialized oral oncology products, at the SPIMACO Pharmaceuticals plant, which manufactures the oncology and high-potency drugs in Saudi Arabia.
Date of Announcement of the Award	2025-10-05 Corresponding to 1447-04-13
Contract Subject Matter	Signing of a contract with Boston Oncology Arabia Limited to transfer technology and enable local manufacturing of four specialized products for Oncology, at the SPIMACO Pharmaceuticals plant, which manufactures the oncology and high-potency drugs in Saudi Arabia.
The Entity with Which the Contract was Signed	Boston Oncology Arabia Limited
Date of Signing the Contract	2025-10-05 Corresponding to 1447-04-13
Contract Value	The value of this agreement is less than 1% of SPIMACO’s total annual revenue for 2024.
Contract Details	According to the agreement between the two companies, Boston Oncology grants SPIMACO a license to manufacture pharmaceutical products for oncology treatment, in two phases: Phase one: Transfer of technology covering a first wave of four oncology molecules. Phase two: Commencement of local manufacturing of these four molecules at SPIMACO’s High Potent Facility in Saudi Arabia. According to the agreement, the number of pharmaceutical products might be increased in the future, and any such additions will be announced at the appropriate time.
Contract Duration	7 Years
Financial Impact and the Relevant Period	The financial impact is currently undetermined but is expected to be positive in the future. Substantial developments in this regard will be announced in due course.
Related Parties	NA
Additional Information	NA

Saudi Pharmaceutical Industries and Medical Appliances Corp. Announces Contract Sign Off with Boston Oncology Arabia Limited